MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

UroGen Pharma Ltd

Fermé

17.05 -4.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.66

Max

17.98

Chiffres clés

By Trading Economics

Revenu

-6.1M

-50M

Ventes

4M

24M

Marge bénéficiaire

-206.236

Employés

253

EBITDA

-4.5M

-41M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+106.68% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-33M

885M

Ouverture précédente

21.53

Clôture précédente

17.05

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

UroGen Pharma Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 juin 2025, 18:34 UTC

Principaux Mouvements du Marché

UroGen Pharma Shares Rise on FDA Approval of Bladder Cancer Drug

16 mai 2025, 19:39 UTC

Principaux Mouvements du Marché

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Comparaison

Variation de prix

UroGen Pharma Ltd prévision

Objectif de Prix

By TipRanks

106.68% hausse

Prévisions sur 12 Mois

Moyen 36.83 USD  106.68%

Haut 47 USD

Bas 31 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

9.625 / 11.64Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Neutral Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
help-icon Live chat